33. CHARACTERISTICS OF HISTOPATHOLOGY, GRADE AND pTNM STAGE OF OPERATED LUNG ADENOCARCINOMA AT THE NATIONAL LUNG HOSPITAL IN 2022

Tran Thi Tuan Anh1, Nguyen Thanh Hoa1, Vo Thi Nhung1, Pham Thi Thu Phuong1, Le Trung Tho2
1 National Lung Hospital
2 Hanoi Medical University

Main Article Content

Abstract

Objective: Describe the histopathological characteristics, histological grade, and Ptnm staging of operated lung adenocarcinoma based on the guidelines of the WHO 2021 classification.


Methods: Cross-sectional descriptive study on patients with operated lung adenocarcinoma (≥18 years old) admitted to the National Lung Hospital from January to December 2022. We collected data on clinical and histopathological characteristics, pTNM stage, histological grade are new points in the 2021 histopathological classification.


Results: 186 patients with operated lung adenocarcinoma were collected and evaluated for target characteristics with a predominance in men (54.8%), smokers (58.1 %); age 60 or older (56.5%) with the largest number being in the 60-69 age group; Stage IB accounts for the highest rate. The most common histopathological type is invasive non-mucinous adenocarcinoma (97.8%), with the dominant acinar eubtype accounting for the highest proportion; histological grade III is the most common with a rate of 51.1%, predominantly in patients over 60 years old, smokers (p < 0.05), stages II, IIIA; The STAS pattern (tumor spread in the air space) appears in 25.8% of cases, accounting for a higher proportion under the dominant micropapillary type and histological grade III (p<0.05) and stage II.


Conclusion: Lung cancer is mainly operated on in men, smokers, from 60 years old. In terms of histopathology, invasive non-mucinous adenocarcinoma accounts for the majority with a high prevalence of cystic cluster type. Most importantly, assessment of histological grade has negative prognostic factors such as poorly differentiated histological grade (grade III), micropapillary morphology and STAS model, stages IIB, IIIA, which are new updates in the classification. WHO 2021 surgical lung cancer tissue types. This is the basis for developing research to monitor and evaluate patients after surgery, and provide adjunctive treatment options for patients.

Article Details

References

[1] MLC. MBS. Cancer Progress and Priorities:
Lung Cancer. Cancer Epidemiol Biomarkers
Prev. 2019;28(10):1563–79.
[2] Krishna Chaitanya Thandra AB KS, John Sukumar
Aluru, Alexander Barsouk. . Epidemiology of lung cancer.
Contemp Oncol (Pozn).2021;25(1):45-52.
[3] N. Duma RS-D JRM. Non–small cell lung cancer:
epidemiology, screening, diagnosis, and
treatment. Mayo Clin Proc. 2019;94:1623-40.
[4] Zahra Khodabakhshi SM HA, Mehrdad Oveisi,
Isaac Shiri, Habib Zaidi. Non-small cell lung
carcinoma histopathological subtype phenotyping
using high-dimensional multinomial multiclass CT
radiomics signature. . Computers in Biology and
Medicine 2021;136:1047-52.
[5] Sara Boukansa ZB SG, et al. . Correlation of
Epidermal Growth Factor Receptor Mutation
With Major Histologic Subtype of Lung Adenocar-
cinoma According to IASLC/ATS/ERS Classification.
Cancer Control. 2022:29.
[6] Board. WCoTE. World Health Organization
classification of tumours: Thoracic tumours
- Fifth edition. Board WCoTE, editor. Lyon:
World Health Organization; 2021.
[7] Vietnam. IAfRoCI. International Agency for Research
on Cancer (IARC). Vietnam. Accessed. 2020.
[8] Liesbeth M. Hondelink SME, Peggy Atmodimedjo,
Danielle Cohen, Janina L. Wolf,
Anne-Marie C. Dingemans, Hendrikus J. Dubbink, Jan
H. von der Thu¨sen. Prevalence, clinical and molecular
characteristics of early stage EGFR-mutated lung cancer
in a real-life WestEuropean cohort: Implications for adjuvant
therapy. European Journal of Cancer 2023;181 53-61.
[9] Amin MB ES, Greene FL, et al.,. AJCC Cancer
Staging Manual. 8th ed: Springer; 2017.
[10] Tsao M. The New WHO Classification of
Lung Tumors. Journal of Thoracic Oncology
2021;16:3S: S63-S7.
[11] T.D C, P.A R, H D, al e. Associations between
the IASLC/ATS/ERS lung adenocarcinoma classification
and EGFR and KRAS mutations. Pathology. 2016;48:17-24.
[12] H U, K K, J.E C, al e. Solid Predominant Histologic Subtype
in Resected Stage I Lung Adenocarcinoma Is an Independent
Predictor of Early,Extrathoracic, Multisite Recurrence and of Poor
Postrecurrence Survival. Journal of Clinical Oncology. 2015;
33(26):2877-84.
[13] Anh TTT. Nghiên cứu đặc điểm mô bệnh học và
sự bộc lộ dấu ấn Hóa mô miễn dịch PD-L1 trong
ung thư biểu mô tuyến phổi [Luận văn thạc sĩ Y
học]. Hà Nội: Trường Đại học Y Hà Nội; 2018.
[14] Thịnh ĐĐ. Đặc điểm mô bệnh học, mối liên
quan giữa đột biến gen EGFR với sự bộc lộ dấu
ấn TTF-1 trên bệnh nhân ung thư biểu mô tuyến
của phổi [Luận Văn]. Hà Nội: Trường Đại Học
Y Hà Nội; 2016.